Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Biosimilars vs Corticosteroids in Noninfectious Uveitis
NCT06310837Completed
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of adalimumab in noninfectious uveitis (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Best Corrected Visual Acuity at 24 weeks. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
noninfectious uveitis
Beyond the preview
Go deeper on NCT06310837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310837.